101 related articles for article (PubMed ID: 16307454)
1. A rabbit model for sublingual drug delivery: comparison with human pharmacokinetic studies of propranolol, verapamil and captopril.
Dali MM; Moench PA; Mathias NR; Stetsko PI; Heran CL; Smith RL
J Pharm Sci; 2006 Jan; 95(1):37-44. PubMed ID: 16307454
[TBL] [Abstract][Full Text] [Related]
2. Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation.
al-Furaih TA; McElnay JC; Elborn JS; Rusk R; Scott MG; McMahon J; Nicholls DP
Eur J Clin Pharmacol; 1991; 40(4):393-8. PubMed ID: 2050174
[TBL] [Abstract][Full Text] [Related]
3. Improving sublingual delivery of weak base compounds using pH(max) concept: application to propranolol.
Wang Y; Zuo Z; Chen X; Tomlinson B; Chow MS
Eur J Pharm Sci; 2010 Feb; 39(4):272-8. PubMed ID: 20060467
[TBL] [Abstract][Full Text] [Related]
4. Effect of pH on sublingual absorption of oxycodone hydrochloride.
Al-Ghananeem AM; Malkawi AH; Crooks PA
AAPS PharmSciTech; 2006 Mar; 7(1):E23. PubMed ID: 16584154
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of buffered propranolol sublingual tablet (Promptol™)-application of a new "physiologically based" model to assess absorption and disposition.
Wang Y; Wang Z; Zuo Z; Tomlinson B; Lee BT; Bolger MB; Chow MS
AAPS J; 2013 Jul; 15(3):787-96. PubMed ID: 23605805
[TBL] [Abstract][Full Text] [Related]
6. The effect of anesthesia on the pharmacokinetics of sublingually administered verapamil in rabbits.
Moench PA; Heran CL; Stetsko PI; Mathias NR; Wall DA; Hussain MA; Smith RL
J Pharm Sci; 2003 Sep; 92(9):1735-8. PubMed ID: 12949993
[No Abstract] [Full Text] [Related]
7. The effect of pH on the buccal and sublingual absorption of captopril.
McElnay JC; al-Furaih TA; Hughes CM; Scott MG; Elborn JS; Nicholls DP
Eur J Clin Pharmacol; 1995; 48(5):373-9. PubMed ID: 8641325
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.
John DN; Fort S; Lewis MJ; Luscombe DK
Br J Clin Pharmacol; 1992 Jun; 33(6):623-7. PubMed ID: 1389935
[TBL] [Abstract][Full Text] [Related]
9. Influence of captopril, propranolol, and verapamil on arterial pulse wave velocity and other cardiovascular parameters in healthy volunteers.
Kähönen M; Ylitalo R; Kööbi T; Turjanmaa V; Ylitalo P
Int J Clin Pharmacol Ther; 1998 Sep; 36(9):483-9. PubMed ID: 9760009
[TBL] [Abstract][Full Text] [Related]
10. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol.
Vogelpoel H; Welink J; Amidon GL; Junginger HE; Midha KK; Möller H; Olling M; Shah VP; Barends DM
J Pharm Sci; 2004 Aug; 93(8):1945-56. PubMed ID: 15236445
[TBL] [Abstract][Full Text] [Related]
11. The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application.
Wong H; Grossman SJ; Bai SA; Diamond S; Wright MR; Grace JE; Qian M; He K; Yeleswaram K; Christ DD
Drug Metab Dispos; 2004 Dec; 32(12):1359-69. PubMed ID: 15333515
[TBL] [Abstract][Full Text] [Related]
12. HO-1-u-1 model for screening sublingual drug delivery--influence of pH, osmolarity and permeation enhancer.
Wang Y; Zuo Z; Chow MS
Int J Pharm; 2009 Mar; 370(1-2):68-74. PubMed ID: 19071203
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil: species differences and influence of endotoxin.
Laethem ME; Belpaire FM; Wijnant P; Bogaert MG
Chirality; 1995; 7(8):616-22. PubMed ID: 8593255
[TBL] [Abstract][Full Text] [Related]
14. Effect of pH on sublingual absorption of oxycodone hydrochloride.
Al-Ghananeem AM; Malkawi AH; Crooks PA
AAPS PharmSciTech; 2006 Mar; 7(1):E163-E167. PubMed ID: 28290038
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters.
Bleske BE; Welage LS; Touchette MA; Edwards DJ; Rodman DP; Shea MJ
Ther Drug Monit; 1994 Apr; 16(2):216-20. PubMed ID: 8009573
[TBL] [Abstract][Full Text] [Related]
16. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
[TBL] [Abstract][Full Text] [Related]
17. Controlled-release formulations of propranolol and verapamil.
Dunn J
J Clin Pharmacol; 1987 Jan; 27(1):22-31. PubMed ID: 3316302
[TBL] [Abstract][Full Text] [Related]
18. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
[TBL] [Abstract][Full Text] [Related]
19. Effects of dosing protocol on distribution of propranolol in periocular tissues after topical ocular instillation.
Liu H; Yang MB; Li SK; Hao J
Curr Eye Res; 2015 May; 40(6):638-45. PubMed ID: 25167079
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability.
Mansur AP; Avakian SD; Paula RS; Donzella H; Santos SR; Ramires JA
Braz J Med Biol Res; 1998 May; 31(5):691-6. PubMed ID: 9698776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
